Can PharmaEssentia turn ropeginterferon into a broader myeloproliferative neoplasm franchise?
PharmaEssentia’s ET data arrive before a key FDA date. Ropeginterferon could shift timing, sequencing, and risk thinking in MPN care.
PharmaEssentia expands beyond Taiwan with Puerto Rico plant as BESREMi growth plans widen
PharmaEssentia’s Puerto Rico facility could reshape BESREMi supply resilience and U.S. expansion. Read what this means for biologics strategy.
PharmaEssentia Corporation secures Japan approval for high-dose BESREMi regimen in polycythemia vera
Japan approves high-dose BESREMi regimen for polycythemia vera. Read the full analysis on safety, adoption, and what clinicians will watch next.